I-Mab Announces Upcoming Participation at January Conferences
12/31/2021 - 08:00 AM
SHANGHAI and GAITHERSBURG, MD ., Dec. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences in January 2022 . Details of the conferences and management presentation are as follows:
40th Annual J.P. Morgan Healthcare Conference
Presentation: Tuesday, January 11, 2022 , at 4:30 p.m. E.S.T.
Presenter: Dr. Jingwu Zang , Founder, Chairman, Acting CEO and Director
Webcast link: https://jpmorgan.metameetings.net/events/healthcare22/sessions/40371-i-mab-biopharma/webcast?gpu_only=true&kiosk=true The webcast will also be available under "Event Calendar" on IMAB's IR website at http://ir.i-mabbiopharma.com/ .
One-on-one and small group meetings: January 19-21, 2022
Management participants: Dr. Jingwu Zang , Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu , Director and President, Mr. John Long , Director and Chief Financial Officer, Mr. Tianyi Zhang , Vice President Investor Relations, Mr. Tyler Ehler , Senior Director Investor Relations and Phoebe Peng , Associate Director Investor Relations
For more information, please contact your J.P. Morgan representative.
Morgan Stanley Virtual China New Economy Summit 2022
One-on-one and small group meetings: January 5-7, 2022
Management participants: Dr. Jingwu Zang , Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu , Director and President, Mr. John Long , Director and Chief Financial Officer, Mr. Tianyi Zhang , Vice President Investor Relations, Mr. Tyler Ehler , Senior Director Investor Relations and Phoebe Peng , Associate Director Investor Relations
For more information, please contact your Morgan Stanley representative.
H.C. Wainwright Virtual BioConnect Conference
One-on-one and small group meetings: January 10 - 13, 2021
Management participants: Dr. Jingwu Zang , Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu , Director and President, Mr. John Long , Director and Chief Financial Officer, Mr. Tianyi Zhang , Vice President Investor Relations, Mr. Tyler Ehler , Senior Director Investor Relations and Phoebe Peng , Associate Director Investor Relations
For more information, please contact your H.C.Wainwright representative.
UBS Greater China Conference 2022
One-on-one and small group meetings: January 11-14, 2022
Management participants: Dr. Jingwu Zang , Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu , Director and President, Mr. John Long , Director and Chief Financial Officer, Mr. Tianyi Zhang , Vice President Investor Relations, Mr. Tyler Ehler , Senior Director Investor Relations and Phoebe Peng , Associate Director Investor Relations
For more information, please contact your UBS representative.
About I-Mab
I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its internal discovery and global partnerships for in-licensing, based on the Company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies. The Company is progressing from a clinical-stage biotech company into a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, a world-class GMP manufacturing facility, and commercial capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing , Hangzhou , Guangzhou , Lishui and Hong Kong in China , and Maryland and San Diego in the United States . For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn , Twitter , and WeChat .
For more information, please contact:
I-Mab Contacts
Investor Inquiries:
The Piacente Group, Inc.Emilie Wu E-mail: emilie@thepiacentegroup.com Office line: + 86 21 6039 8363
View original content:https://www.prnewswire.com/news-releases/i-mab-announces-upcoming-participation-at-january-conferences-301452230.html
SOURCE I-Mab